Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Hydroxyurea

Review the clinical trials studying hydroxyurea on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-14 of 14

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Status: Active
Location: 10 locations
A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
Status: Active
Location: 8 locations
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Status: Active
Location: 6 locations
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Active
Location: 2 locations
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Response-Adaptive Chemoradiation after Induction Therapy for the Treatment of Patients with Locally Advanced Head and Neck Squamous Cell Cancer
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Reduced Intensity Conditioning Regimen for the Treatment of Non-Malignant Disorders
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
Status: Active
Location: Yale University, New Haven, Connecticut
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Status: Active
Location: Yale University, New Haven, Connecticut
Tislelizumab and Pamiparib in Combination with Concurrent Chemotherapy and Radiation Therapy for the Treatment of Patients with Previously Treated Recurrent Head and Neck Squamous Cell Carcinoma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Ziftomenib for the Treatment of Patients with NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Status: Approved
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Approved
Location: Roswell Park Cancer Institute, Buffalo, New York
TCRalpha/beta and CD19+ depleted Hematopoietic Stem Cell Transplant from Closely Matched Unrelated Donors or Haploidentical Related donors for Blood Disorders in Children and Young Adults
Status: Approved
Location: 2 locations
Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Treating Patients with CD7+ Hematologic Cancers
Status: Temporarily Closed to Accrual
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri